Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on Capital EmployedReturn on Invested CapitalTimes Interest Earned

Lifecore Biomedical, Inc. \De\ (LFCR) EBITDA Margin (2016 - 2025)

Lifecore Biomedical, Inc. \De\ has reported EBITDA Margin over the past 16 years, most recently at 14.62% for Q2 2025.

  • For Q2 2025, EBITDA Margin rose 894.0% year-over-year to 14.62%; the TTM value through May 2025 reached 13.38%, down 2995.0%, while the annual FY2025 figure was 13.38%, 649.0% down from the prior year.
  • EBITDA Margin for Q2 2025 was 14.62% at Lifecore Biomedical, Inc. \De\, up from 25.68% in the prior quarter.
  • Over five years, EBITDA Margin peaked at 47.16% in Q4 2023 and troughed at 149.47% in Q4 2021.
  • A 5-year average of 29.15% and a median of 23.5% in 2023 define the central range for EBITDA Margin.
  • Biggest five-year swings in EBITDA Margin: plummeted -10073bps in 2023 and later skyrocketed 18136bps in 2024.
  • Year by year, EBITDA Margin stood at 149.47% in 2021, then surged by 62bps to 57.26% in 2022, then surged by 182bps to 47.16% in 2023, then plummeted by -113bps to 6.02% in 2024, then skyrocketed by 343bps to 14.62% in 2025.
  • Business Quant data shows EBITDA Margin for LFCR at 14.62% in Q2 2025, 25.68% in Q1 2025, and 6.02% in Q4 2024.